CAC vs MLTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CAC · Camden National$58.02 ▲ 0.17%
MLTX · MoonLake Immunotherapeutics$11.53 ▲ 6.76%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CAC +53.2%
- MLTX +6.6%
Head to head
| Metric | CAC | MLTX |
|---|---|---|
| Price | $58.02 | $11.53 |
| Change today | ▲ 0.17% | ▲ 6.76% |
| Market cap | $980.09M | $981.28M |
| Return, 3 months | +1.1% | -33.5% |
| Return, year to date | +37.2% | -12.5% |
| Return, 1 year | +53.3% | +8.5% |
| P/E (TTM) | 10.9 | -3.2 |
| P/B | 1.4 | 2.6 |
| P/E percentile vs own 5y | 52nd | 90th |
| Dividend yield | 2.90% | – |
| Revenue growth (YoY, latest qtr) | +6.2% | – |
| Net profit growth (YoY) | +7.7% | -10.3% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | 34.5% | – |
| Return on equity | 12.9% | -67.4% |
| Analyst target vs. price | +1.7% | +177.5% |
| Analyst buy share | 0% | 88% |
| RSI (14) | 53 | 49 |
| 30-day volatility | 23.9% | 69.7% |
| Max drawdown, 1 year | -11.3% | -56.9% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MLTX is the largest of the group by market value.
- CAC has returned the most over the past year.
- MLTX carries the lowest trailing P/E.
- CAC has been the calmest stock over the last 30 days.